The FDA has approved the use of Janssen Biotech, Inc’s immunotherapy Darzalex in combination with pomalidomide and dexamethasone. Darzalex is used to treat multiple myeloma patients who have previously received at least 2 therapies with lenalidomide and a proteasome inhibitor.
The FDA has approved the use of Janssen Biotech, Inc’s immunotherapy Darzalex in combination with pomalidomide and dexamethasone. Darzalex is used to treat multiple myeloma patients who have previously received at least 2 therapies with lenalidomide and a proteasome inhibitor.
In 2015, Darzalex was first approved as a monotherapy treatment for multiple myeloma patients who received at least 3 prior lines of therapy. Then in 2016, the drug received new FDA approvals to treat multiple myeloma patients with at least 1 prior therapy and in combination with lenalidomide and dexamethasone, or bortezomib and dexamethasone.
"Despite tremendous progress, most patients with multiple myeloma continually relapse or become resistant to available therapies, such as [proteasome inhibitors] and immunomodulatory agents,” Ajai Chari, MD, an associate professor of medicine for the Multiple Myeloma Program and associate director of Clinical Research at Mount Sinai Hospital, said in a statement.
The FDA approved use of Darzalex in combination following the results of the phase 1b EQUULEUS study. The study included 103 multiple myeloma patients who had received a prior proteasome inhibitor and immunomodulatory agent. The participants then received 16 mg/kg of Darzalex with pomalidomide and low-dose dexamethasone. This treatment was continued until the disease progressed.
The data showed that Darzalex combined with pomalidomide and dexamethasone results in an overall response rate of 59.2%, with very good partial response in 28.2% of patients, complete response in 5.8%, stringent complete response in 7.8%, and partial response was achieved in 17.5% of patients.
"The recent approval of Darzalex is significant for patients and clinicians who urgently need new options and regimens,” said Peter F. Lebowitz, MD, PhD, from the Global Oncology Head at Janssen Research & Development, LLC. “This milestone underscores the versatility of Darzalex with a range of treatment regimens. We look forward to continued study of daratumumab in earlier stages of multiple myeloma and other cancers."
Early Involvement Critical in Treating Immunotherapy-Induced Overlap Syndrome
April 19th 2024A series of case studies reveals the importance of early diagnosis and involvement of special teams of clinicians when dealing with potential cases of overlap syndrome, which encompasses myocarditis, myasthenia gravis, and immune checkpoint inhibitor–related myositis.
Read More
Real-World Study Reveals Key Insights Into DLBCL Treatment Patterns, Outcomes
April 18th 2024A recent study offers valuable insights into the characteristics, treatment patterns, and outcomes of diffuse large B-cell lymphoma (DLBCL) in patients across different lines of therapy, providing a look into the landscape of DLBCL management.
Read More
Oncology Onward: A Conversation With Penn Medicine's Dr Justin Bekelman
December 19th 2023Justin Bekelman, MD, director of the Penn Center for Cancer Care Innovation, sat with our hosts Emeline Aviki, MD, MBA, and Stephen Schleicher, MD, MBA, for our final episode of 2023 to discuss the importance of collaboration between academic medicine and community oncology and testing innovative cancer care delivery in these settings.
Listen
Pegcetacoplan for PNH More Cost-Effective Than Anti-C5 Monoclonal Antibodies
April 18th 2024A cost-utility analysis conducted from the perspective of the Italian health system found that pegcetacoplan was more effective and less costly than 2 complement 5 (C5) inhibitors for the treatment of paroxysmal nocturnal hemoglobinuria (PNH).
Read More